Earnings Call Summary | Balchem(BCPC.US) Q2 2024 Earnings Conference
Earnings Call Summary | Balchem(BCPC.US) Q2 2024 Earnings Conference
The following is a summary of the Balchem Corporation (BCPC) Q2 2024 Earnings Call Transcript:
以下是拜切公司（BCPC）2024年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Balchem reported a Q2 revenue of $234 million, a 1.2% increase year-over-year.
Gross margin expanded by 210 basis points to 35.5%, with gross margin dollars growing 7.3%.
Q2 net income was $32 million, up 6.5% year-over-year, yielding earnings per share of $0.98 on a GAAP basis and $1.09 on a non-GAAP basis.
Record quarterly adjusted EBITDA of $62 million, marking a 5% increase, with an adjusted EBITDA margin of 26.6%.
Balchem報告Q2營業收入2.34億美元，同比增長1.2%。
毛利率擴大210個點子至35.5%，毛利潤增長7.3%。
Q2淨利潤爲3200萬美元，同比增長6.5%，基於GAAP基準的每股收益爲0.98美元，基於非GAAP基準的每股收益爲1.09美元。
創下了6200萬美元的季度調整後EBITDA紀錄，增長5%，調整後EBITDA利潤率爲26.6%。
Business Progress:
業務進展：
Continued strong performance in Human Nutrition & Health, driven by minerals, nutrients, and vitamins, with sales up 9%.
Launched a new product, Optifolin+, a choline-enriched bioactive reduced folate contributing to the company's innovative edge.
Specialty Product segment, mainly performance gases, reflected healthy sales growth with a 7.2% increase.
Early signs of recovery in Animal Nutrition & Health segment with new product introductions expected to boost performance.
人體營養與健康表現持續強勁，主要由礦物質、營養素和維生素推動，銷售額增長9%。
推出了一款新產品Optifolin+，是一種富含膽鹼的生物活性還原葉酸，有助於公司保持創新優勢。
專業產品領域，主要是性能氣體，反映出健康的銷售增長，增長7.2%。
動物營養與健康領域顯示出復甦的早期跡象，預計新產品介紹將推動業績表現。
Opportunities:
機會：
The introduction of Optifolin+, targeting a $1.5 billion market of folic acid, representing potential substantial revenue growth from this new bioactive product.
The market positions and innovative product offerings enhance the company's potential to capitalize on favorable global health and nutrition trends.
Optifolin+的推出，目標是一個15億美元的葉酸市場，代表這一新的生物活性產品有潛在的大量營業收入增長。
市場位置和創新產品的優勢增強了公司利用有利的全球健康與營養趨勢的潛力。
Risks:
風險：
Partial offset in sales growth due to decline in the Animal Nutrition & Health segment.
動物營養與健康領域銷售增長的部分抵消。
More details: Balchem IR
更多細節：拜切IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。